Overcoming MCL-1-driven adaptive resistance to targeted therapies
Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clini...
Saved in:
Main Author: | Kris C. Wood |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/b3104b61e16b45ff87d587459438569d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
by: Dana S. Neel, et al.
Published: (2017) -
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
by: Enkhtsetseg Munkhbaatar, et al.
Published: (2020) -
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
by: Moiez Ali, et al.
Published: (2017) -
Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
by: Matthew J. Sale, et al.
Published: (2019) -
Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer’s disease mouse model
by: Xufeng Cen, et al.
Published: (2020)